TH Global Capital Healthcare & Life Sciences Investment Banking is pleased to announce that it has acted as the exclusive financial advisor to Aqurance S.A, a leading Veeva Premier Services Partner, on its strategic sale to EY. This transaction is TH Global Capital’s second deal advising a Veeva® Platform partner. This transaction further cements the company’s position as the leading boutique investment bank in healthcare and life sciences.
Established in 2011, Aqurance is a leading European Veeva partner with a unique mix of clinical, commercial and digital transformation services. With a dedicated team of 65 employees in Europe, and deep pharma expertise, Aqurance works with for life sciences companies globally. Aqurance’s business aligns closely with EY’s ambition to create a strong Commercial CRM and R&D platform business. By combining Aqurance’s expertise and existing client footprint with EY’s broader consulting offering and larger client network, the combined entity will be able to undertake large transformation engagements and build a powerful and market leading team.
Dionissis Nikolopoulos, Founder & CEO of Aqurance, said, “TH Global Capital Healthcare & Life Sciences Investment Banking was our key partner, bringing expertise and strategic guidance throughout the transaction. The team worked incredibly hard and were always by our side throughout and effortlessly navigated through the transaction, providing us with sound advice and helping us find solutions to any unforeseen challenges. TH Global Capital’s understanding of the Veeva ecosystem, and their global buyer and investor network helped us identify the right strategic partner. We are truly thankful for the TH team’s guidance and unwavering support throughout this process.”
Vivek Subramanyam, Founder and CEO of TH Global Capital, said, “We are incredibly excited to have completed this significant Healthcare & life sciences transaction with EY. This transaction further highlights TH Global Capital’s global reach and deep capabilities in the life sciences and pharma ecosystem. We wish Aqurance every success in their strategic partnership with EY.”
Asif Shahinsha, Executive Director at TH Global Capital Healthcare and Life Sciences Investment Banking added, “We are delighted to have supported and advised Aqurance on this transaction. It was a widely sought asset, reflecting the demand for quality pharma and life sciences services companies in Europe. It has been a pleasure working with Dionissis, Sotiris and the wider team, and we’re excited to see what they’ll accomplish as part of the EY family.”
Find out more about the transaction